FDA Grants Full Approval to Rucaparib for Advanced Prostate Cancer with BRCA Mutations
Table of Contents
Rucaparib (Rubraca), a PARP inhibitor manufactured by Pharmaand GmbH, has received full FDA approval for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) harboring a deleterious BRCA mutation (brcam) who have previously been treated with androgen receptor-directed therapy. This approval, announced on December 17, 2025, marks a notable advancement in treatment options for a challenging disease where treatment options are limited after progression on initial therapies. According to a company release, rucaparib works by blocking PARP enzymes, which are involved in DNA repair, and is particularly effective in cancers with defects in BRCA genes.
the recommended dosage of rucaparib is 600 mg – two 300 mg tablets – taken orally twice daily, with or without food, for a total daily dose of 1200 mg. Treatment should continue until disease progression or unacceptable toxicity occurs.
TRITON3 Trial Paves the Way for Approval
The FDA’s decision follows positive results from the TRITON3 trial (NCT02975934), a phase 3, randomized, open-label study. This trial was crucial in confirming the efficacy and clinical benefit of rucaparib, building upon its initial accelerated approval in May 2020. The study enrolled 405 patients with mCRPC, with 302 identified as having BRCAm and 103 with ATM mutations (ATMm). All participants had previously progressed on an androgen receptor pathway inhibitor (ARPI) and had not received prior chemotherapy in the castration-resistant setting.
Patients were randomly assigned to receive either rucaparib, a physician’s choice of another ARPI (enzalutamide or abiraterone acetate), or docetaxel. Randomization considered factors like performance status, the presence of liver metastases, and the specific type of mutation – BRCA1m, BRCA2m, or ATMm. All patients also maintained castrate levels of testosterone through androgen deprivation therapy or surgical castration.
Significant Progression-Free Survival Gains
At the 62-month follow-up point, the TRITON3 trial demonstrated a statistically significant enhancement in imaging-based progression-free survival (PFS) with rucaparib compared to the control groups. The median PFS for patients with BRCAm receiving rucaparib was 11.2 months, versus 6.4 months for those receiving other treatments (HR,0.50 [95% CI, 0.36-0.69]). This benefit was also observed in the intention-to-treat group,with a median PFS of 10.2 months for rucaparib compared to 6.4 months for controls (HR, 0.61 [95% CI, 0.47-0.80]; P < .001 for both comparisons).
An exploratory analysis of the ATMm subgroup showed a trend toward improved PFS with rucaparib, though the results were not statistically significant (median PFS: 8.1 months vs. 6.8 months; HR, 0.95 [95% CI, 0.59-1.52]).
Managing Side Effects and Safety Considerations
The most commonly reported adverse events (AEs) associated with rucaparib were fatigue, nausea, and anemia. The TRITON3 investigators emphasized that treatment interruption or dose reduction should be considered to manage these side effects. Importantly, no cases of myelodysplastic syndrome or acute myeloid leukemia were reported during the trial, and the risk of thromboembolic events was comparable to that of control medications.
Though, the FDA’s prescribing data for rucaparib includes warnings and precautions regarding the potential for myelodysplastic syndrome/acute myeloid leukemia and embryo-fetal toxicity.
This approval offers a new and potentially life-extending treatment option for men with advanced prostate cancer and BRCA mutations, representing a significant step forward in personalized cancer care.
